These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 454969)

  • 1. Assay of liver membrane insulin receptors in obese, hyperglycaemic (ob/ob) mice: stimulant effect of an oral antidiabetic sulphonylurea drug [proceedings].
    Greenstein BD
    Br J Pharmacol; 1979 May; 66(1):86P. PubMed ID: 454969
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved insulin receptor assay: effects of an antidiabetic sulphonylurea on liver membrane insulin receptors from obese hyperglycaemic mice.
    Greenstein BD
    Br J Pharmacol; 1979 Jun; 66(2):317-22. PubMed ID: 465886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of glimepiride on the binding kinetics of insulin with its skeletal muscle and liver receptors in rats with short term and prolonged hyperglycemia induced by streptozotocin.
    Krauss H; Grzymisławski M; Koźlik J; Sosnowski P; Piatek J; Mikrut K; Maćkowiak P; Paluszak J
    Med Sci Monit; 2004 Jan; 10(1):BR11-6. PubMed ID: 14704628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
    Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
    Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine abnormalities in the pancreas and gut of the obese hyperglycaemic (ob/ob) mouse [proceedings].
    Adrian TE; Bryant MG; Bloom SR
    J Endocrinol; 1979 May; 81(2):156P. PubMed ID: 458334
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
    Ide T; Tsunoda M; Mochizuki T; Murakami K
    Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Physiologic and physiopathologic implications of insulin-receptor interaction (II). Pathologic situations in which changes in insulin-receptor interaction are detected].
    Durán García S; Hernández Herrero C
    Med Clin (Barc); 1984 Apr; 82(14):639-45. PubMed ID: 6376967
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of chronic tolbutamide administration on normal and obese-hyperglycemic mice: evidence for post-receptor potentiation of insulin action.
    Poyet C; Feldman JM
    Res Commun Chem Pathol Pharmacol; 1982 Mar; 35(3):355-76. PubMed ID: 7043679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihyperglycaemic effect of saccharin in diabetic ob/ob mice.
    Bailey CJ; Day C; Knapper JM; Turner SL; Flatt PR
    Br J Pharmacol; 1997 Jan; 120(1):74-8. PubMed ID: 9117102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental studies on the problem of insulin resistance in adipositas and diabetes mellitus, with the aid of New Zealand obese mice. Pathogenesis of the obese-hyperglycaemic syndrome (author's transl)].
    Huchzermeyer H; Rudorff KH; Staib W
    Z Klin Chem Klin Biochem; 1973 Jun; 11(6):249-56. PubMed ID: 4754106
    [No Abstract]   [Full Text] [Related]  

  • 11. Glucose metabolism in the obese hyperglycaemic (C57B1/6 ob/ob) mouse: the effects of fasting on glucose turnover rates.
    Smith SA; Cawthorne MA; Simson DL
    Diabetes Res; 1986 Feb; 3(2):83-6. PubMed ID: 3698484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular loci of sulfonylurea actions.
    Lebovitz HE
    Diabetes Care; 1984; 7 Suppl 1():67-71. PubMed ID: 6376031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic effects of oral hypoglycemic drugs.
    Davidoff F
    Fed Proc; 1977 Dec; 36(13):2724-7. PubMed ID: 336410
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin receptors in man. The monocyte as model for insulin receptor studies.
    Beck-Nielsen H
    Dan Med Bull; 1980 Sep; 27(4):173-85. PubMed ID: 7002490
    [No Abstract]   [Full Text] [Related]  

  • 15. Sulfonylurea effects on target tissues for insulin.
    McCaleb ML; Maloff BL; Nowak SM; Lockwood DH
    Diabetes Care; 1984; 7 Suppl 1():42-6. PubMed ID: 6376028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glibornuride, a new high-effective antidiabetic agent. Pharmacological and biochemical comparative studies in various animal species and animal experimental models].
    Lorch E; Gey KF; Sommer P
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2154. PubMed ID: 4198964
    [No Abstract]   [Full Text] [Related]  

  • 17. Heterogeneity of glucagon-like immunoreactive peptides (GLi) in the intestine of obese hyperglycaemic (ob/ob) mice.
    Flatt PR; Bailey CJ; Swanston-Flatt SK
    Horm Metab Res; 1983 Jun; 15(6):308-9. PubMed ID: 6688235
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mode of action of oral antidiabetic drugs].
    Frey H
    Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1591-5. PubMed ID: 4588814
    [No Abstract]   [Full Text] [Related]  

  • 19. [Extrapancreatic effects of sulfonylurea compounds. IV. Increase of the effect of insulin due to tolbutamide, glibornuride, and glibenclamide in vitro].
    Beyer J; Gather W; Schöffling K
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2179. PubMed ID: 4198966
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of biguanides and sulfonylureas on insulin receptors in cultured cells.
    Goldfine ID; Iwamoto Y; Pezzino V; Trischitta V; Purrello F; Vigneri R
    Diabetes Care; 1984; 7 Suppl 1():54-8. PubMed ID: 6734405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.